- Home
- JANX vs OMCL Comparison
JANX vs OMCL Comparison
Compare JANX & OMCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- OMCL
- Stock Information
- Founded
- JANX 2017
- OMCL 1992
- Country
- JANX United States
- OMCL United States
- Employees
- JANX N/A
- OMCL N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- OMCL Computer Manufacturing
- Sector
- JANX Health Care
- OMCL Technology
- Exchange
- JANX Nasdaq
- OMCL Nasdaq
- Market Cap
- JANX 1.4B
- OMCL 1.5B
- IPO Year
- JANX 2021
- OMCL 2001
- Fundamental
- Price
- JANX $23.98
- OMCL $32.11
- Analyst Decision
- JANX Strong Buy
- OMCL Buy
- Analyst Count
- JANX 9
- OMCL 7
- Target Price
- JANX $85.00
- OMCL $46.71
- AVG Volume (30 Days)
- JANX 745.4K
- OMCL 549.1K
- Earning Date
- JANX 08-07-2025
- OMCL 10-29-2025
- Dividend Yield
- JANX N/A
- OMCL N/A
- EPS Growth
- JANX N/A
- OMCL N/A
- EPS
- JANX N/A
- OMCL 0.49
- Revenue
- JANX $439,000.00
- OMCL $1,149,529,000.00
- Revenue This Year
- JANX N/A
- OMCL $5.37
- Revenue Next Year
- JANX $591.60
- OMCL $3.67
- P/E Ratio
- JANX N/A
- OMCL $67.08
- Revenue Growth
- JANX N/A
- OMCL 6.39
- 52 Week Low
- JANX $21.97
- OMCL $22.66
- 52 Week High
- JANX $71.71
- OMCL $55.75
- Technical
- Relative Strength Index (RSI)
- JANX 49.92
- OMCL 52.90
- Support Level
- JANX $22.41
- OMCL $31.90
- Resistance Level
- JANX $24.00
- OMCL $33.75
- Average True Range (ATR)
- JANX 1.10
- OMCL 0.87
- MACD
- JANX 0.01
- OMCL -0.10
- Stochastic Oscillator
- JANX 42.20
- OMCL 31.95
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About OMCL Omnicell Inc. ($0.001 par value)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.